Latest News & Updates
TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.
Last week, the FDA expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
The Hispanic population in the United States represents the fastest-growing segment of the population (expected to reach 30% of the nation’s total by 2050), and faces significant cancer health disparities
Myeloma survivors owe much to Robert A. Kyle’s reluctance to perform autopsies or to undergo cardiac catheterization.
Approximately 85% of patients with newly diagnosed melanoma present with what appears to be clinically localized disease, making them candidates for standard treatment with surgery.
Latest Peer Exchange Discussions
Panelists discuss the frontline administration of ALK and EGFR inhibitors for patients with advanced non-small cell lung caner. View Now
Brian Rini, MD, Janice Dutcher, MD, and Daniel Heng, MD, MPH, discuss clinical trial results in first-line therapy for renal cell carcinoma. View Now
Panelists discuss the importance of patient education for managing the side effects associated with sorafenib in radioactive iodine-refractory differentiated thyroid cancer. View Now
In this segment, Noopur Raje, MD, Sagar Lonial, MD, and Ann McNeill, RN, MSN, APN, discuss adverse events commonly associated with agents used for the treatment of multiple myeloma, and describe how they manage patients who experience adverse events. View Now
Most Popular Right Now
Online CME Activities